Eligo Bioscience
eligo.bioLocations
Île-de-France, France · Paris, France
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Series B
founded in
2014
Eligobiotics is a developer of antibiotics intended to treat microbiome precision and bacteria-associated diseases. The company's antibiotics combine CRISPR/Cas system with engineered phage capsids, to develop antimicrobials that are used to eradicate resistant pathogens or virulent bacteria within the human microbiome, enabling clients to get next-generation antimicrobials to treat diseases caused by superbugs.
Something looks off?Open jobs at Eligo Bioscience
On-site & Remote
Job function
Seniority
Salary